Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia (CLL) treated with the cyclin dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46%...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Kristie A., Ruppert, Amy S., Woyach, Jennifer A., Jones, Jeffrey A., Andritsos, Leslie, Flynn, Joseph M., Rovin, Brad, Villalona-Calero, Miguel, Ji, Jia, Phelps, Mitchell, Johnson, Amy J., Grever, Michael R., Byrd, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162125/
https://www.ncbi.nlm.nih.gov/pubmed/21606960
http://dx.doi.org/10.1038/leu.2011.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162125/
https://www.ncbi.nlm.nih.gov/pubmed/21606960
http://dx.doi.org/10.1038/leu.2011.109

Ejemplares similares